株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

RNAi技術と世界市場

RNAi Technologies and Global Markets

発行 BCC Research 商品コード 166047
出版日 ページ情報 英文 176 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
RNAi技術と世界市場 RNAi Technologies and Global Markets
出版日: 2016年01月18日 ページ情報: 英文 176 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界のRNA干渉技術市場は、2015年の2億6,210万米ドルから2020年にかけCAGR8.4%で拡大し、3億9,260万米ドルになると予測されています。

レポートでは、世界のRNAi技術市場の概要と動向、2020年までの成長予測、技術動向、RNAi研究ツール、試薬、薬剤開発、診断、農業における商業的機会、および参入企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 概要

  • リボ核酸
  • RNA干渉(RNAi)
  • RNA干渉ドラッグデリバリー
  • RNAi創薬と開発
  • その他の潜在的応用

第4章 新規開発と法規制活動

  • 新規開発
  • 法規制の側面
  • 連携的治験と将来的活動

第5章 市場分析

  • 技術別市場
  • 市場シェア
  • RNA干渉研究ツールと試薬
  • 治療薬
  • 世界の医薬品市場
  • RNAi診断薬
  • 農業におけるRNA干渉
  • 地域別市場

第6章 業界構造

  • 研究ツールと試薬
    • 市場リーダー
    • 市場シェア
  • 診断薬
    • 市場リーダー
    • 市場シェア

第7章 特許分析

第8章 現状

第9章 企業プロファイル

第10章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BIO127B

REPORT HIGHLIGHTS

The global market for RNA Interference technologies is expected to grow from $262.1 million in 2015 to $392.6 million in 2020, registering a compound annual growth rate (CAGR) of 8.4%.

This report provides:

  • An overview of the global market for RNAi technologies which are used in the areas of drug delivery, therapeutics, and diagnostics
  • Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020
  • A breakdown of the technologies: RNAi for drug delivery (by nanoparticle delivery, nucleic acid delivery, aptamer delivery); RNAi for drug discovery and therapeutics (by diseases); RNAi for disease diagnostics and biomarker development (by diseases); and RNAi for reagents, research tools, and other applications (by application)
  • Examination of significant deals in the RNAi technologies sector during the last decade
  • A look at commercial opportunities in the RNAi research tools and reagents, drug development, diagnostic, and agriculture markets
  • Profiles of major players in the industry

SCOPE OF THE STUDY

BCC Research conducted the market assessment, the global and regional breakdown of sales data, market projection for the commercial RNAi technologies, application of the techniques in commercial sector as well as in research and development. Further, BCC Research offers the details of new developments, patent analysis, market leaders and market share, etc. for the RNAi technologies and its applications.

The report summarizes the global RNAi technologies market by category and by region. The RNAi market is analyzed based on RNAi research tools and reagents as well as on RNAi diagnostics. The research tools and reagents and therapeutics considered in this report are mainly for small/short interfering RNAs (siRNAs) and diagnostics are mainly based on microRNAs (miRNAs).

MicroRNA (miRNA) research tools, services, drug discovery etc. are excluded from this report; however, these areas are worth a separate report and thus are analyzed in BCC Research report BIO115B in detail. U.S. and non-U.S. markets are considered for the geographical market analysis. The prospective application of RNAi therapeutics in various disease classifications such as oncological, cardiovascular, neurodegenerative, ophthalmologic and others are discussed. The application and progress of RNAi technologies in agriculture is also discussed in this report.

BCC Research verified the sales data for the global and regional RNAi markets for the present and projected values through statistical analysis. The tools/technology details in the report are based on their present and their prospective application and suitability.

ANALYST CREDENTIALS

The study has been carried out by a team of professionals in the biotechnology industry. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. She was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, 2013-2020 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • RIBONUCLEIC ACID (RNA)
    • EVOLUTION OF RNA
      • TABLE 1: EVOLUTION OF RNA
  • RNA INTERFERENCE (RNAI)
    • MECHANISM OF ACTION OF RNA INTERFERENCE
      • MicroRNA (miRNA)
        • TABLE 2: MICRORNA (MIRNA) DATABASES
      • Short Interfering RNA (siRNA)
        • TABLE 3: SHORT/SMALL INTERFERING RNA (SIRNA) DATABASES
      • Small Hairpin RNA (shRNA)
      • Piwi-Interacting RNA (piRNA)
        • TABLE 4: PIWI-INTERACTING RNA (PIRNA) DATABASES
  • RNA INTERFERENCE DRUG DELIVERY
    • SYSTEMIC ELIMINATION OF SIRNA
    • SIRNA STABILITY IN BLOODSTREAM
    • RETICULOENDOTHELIAL SYSTEM (RES) ENTRAPMENT
    • VASCULAR ENDOTHELIUM
    • DIFFUSION
    • PLASMA MEMBRANE
    • ENDOSOMAL ENTRAPMENT
    • NANO-CARRIER MEDIATED TOXICITY
    • METHODS OF RNA INTERFERENCE DRUG DELIVERY SYSTEMS
      • Physical RNAi Delivery Methods
        • Hydrodynamic Injection
        • Electroporation
      • Vector-Based RNAi Delivery Methods
        • Plasmid Vector RNAi Delivery
        • Virus Vector RNAi Delivery
      • Carrier-Based Nonviral RNAi Delivery
        • Cationic Cell-Penetrating Peptide (CPP)
        • Aptamer
        • Lipid-Based siRNA Delivery
          • TABLE 5: STABILIZATION METHODS FOR LIPID BASED SIRNA DELIVERY SYSTEM
      • Polymer- and Peptide-Based Vector
      • Lipid-Polymer Combination
      • Dendrimers
      • Phi29 Packaging RNA
      • Mesoporous Silica Nanoparticles
      • Antibodies
      • Stem Cell
      • Light-Controlled Delivery
      • Quaternized Starch Based Carrier
  • RNAI DRUG DISCOVERY AND DEVELOPMENT
    • RNA-BASED THERAPIES
      • Antisense RNA Therapy
      • Ribosome RNA Therapy
      • Aptamer RNA Therapy
      • Messenger RNA (mRNA) Therapeutics
      • RNAi Therapeutics
        • Drug Discovery
          • Targeting miRNA Processes
          • Delivering Designed siRNAs Into Cells
        • Drug Target Validation
        • Designing RNAi Therapeutics
          • Sequence Selection
          • Chemical and Structure Modification
        • Drug Development
          • RNAi Instability
          • Off-Target Effects
          • Innate/Intrinsic Immune Response
          • Delivery Material Toxicity
          • Saturation of RNAi Machinery
  • OTHER POTENTIAL APPLICATIONS OF RNA INTERFERENCE
    • DIAGNOSTICS
    • AGRICULTURE

CHAPTER 4 - NEW DEVELOPMENTS AND REGULATORY ACTIVITY

  • NEW DEVELOPMENTS
    • TABLE 6: NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF RNAI THERAPEUTICS AND TECHNOLOGIES AS OF SEPTEMBER 2015
  • REGULATORY ASPECTS
    • REGULATORY DEVELOPMENTS
  • COLLABORATIVE TRIALS AND FUTURE ACTIVITIES

CHAPTER 5 - MARKET ANALYSIS

  • MARKET BY TECHNOLOGY
    • TABLE 7: GLOBAL REVENUE FOR RNAI TECHNOLOGIES BY TYPE, THROUGH 2020 ($ MILLIONS)
    • FIGURE 1: GLOBAL REVENUE FOR RNAI TECHNOLOGIES BY TYPE, 2013-2020 ($ MILLIONS)
  • MARKET SHARE
    • TABLE 8: MARKET SHARE OF RNAI TECHNOLOGIES BY TYPE, 2014 (%)
    • FIGURE 2: MARKET SHARE OF RNAI TECHNOLOGIES BY TYPE, 2014 (%)
  • RNA INTERFERENCE RESEARCH TOOLS AND REAGENTS
    • RNAi Research Tools and Constructs
      • TABLE 9: MODIFICATIONS OF SIRNA
      • TABLE 10: RNAI VECTORS
      • Reagents
    • Market Overview
    • Market Revenue
      • TABLE 11: GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 3: GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS, 2013-2020 ($ MILLIONS)
    • Market Share
      • TABLE 12: MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
      • FIGURE 4: MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
  • RNAI INTERFERENCE THERAPEUTICS
    • TABLE 13: DISEASE-SPECIFIC TARGET GENES/PROTEINS FOR RNAI THERAPEUTICS
  • GLOBAL PHARMACEUTICAL MARKET
    • TABLE 14: GLOBAL PHARMACEUTICAL MARKET, THROUGH 2020 ($ BILLIONS)
    • FIGURE 5: GLOBAL PHARMACEUTICAL SALES MARKET,2013-2020 ($ BILLIONS)
    • Market Share of Pharmaceutical Products by Region
      • TABLE 15: GLOBAL PHARMACEUTICAL MARKET SHARES BY REGION, 2014 (%)
      • FIGURE 6: GLOBAL PHARMACEUTICAL MARKET SHARES BY REGION, 2014 (%)
    • Sales of Top Pharmaceutical Companies
      • TABLE 16: TOP GLOBAL PHARMACEUTICAL COMPANIES BY SALES, 2014 ($ MILLIONS)
    • Diseases
      • Cardiovascular Disease
      • Pulmonary Disease
      • Central Nervous System (CNS) Disease
        • Alzheimer's Disease (AD)
        • Parkinson's Disease (PD)
        • Huntington's Disease (HD)
      • Oncology
        • Breast Cancer
        • Pancreatic Cancer
        • Ovarian Cancer
        • Liver Cancer
        • Renal Cancer
        • Colon Cancer
        • Lung Cancer
        • Brain Tumor
        • Prostate Cancer
      • Age-Related Macular Degeneration (AMD)
      • Global Outlook of Therapeutic Spending for Certain Diseases
        • TABLE 17: GLOBAL OUTLOOK OF THERAPEUTIC SPENDING BY DISEASE, THROUGH 2018 ($ BILLION/%)
      • Market Overview
  • RNAI DIAGNOSTICS
    • TABLE 18: NUMBER OF PUBLICATIONS ASSOCIATED WITH MIRNA AND DISEASES, OCTOBER 2015
    • miRNA in Cancer Diagnostics
      • TABLE 19: MIRNA IN VARIOUS CANCER TYPES
      • TABLE 20: MIRNA AND TARGET GENE PAIRS IN VARIOUS CANCER TYPES
    • miRNAs as Diagnostic, Prognostic and Predictive Biomarkers
      • TABLE 21: BIOMARKERS IN VARIOUS CANCER TYPES
    • Market Overview
    • Market Revenue
      • TABLE 22 GLOBAL REVENUE MARKET FOR RNAI DIAGNOSTICS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 7 GLOBAL REVENUE MARKET FOR RNAI DIAGNOSTICS, 2013-2020 ($ MILLIONS)
    • Revenue for Global mRNA Research Tools Market
      • TABLE 23: GLOBAL REVENUE FOR MIRNA RESEARCH TOOLS, THROUGH 2020 ($ MILLIONS)
      • FIGURE 8: GLOBAL REVENUE FOR MIRNA RESEARCH TOOLS,2013-2020 ($ MILLIONS)
  • RNA INTERFERENCE IN AGRICULTURE
    • Virus Control Through RNAi
    • Safety Concerns
      • TABLE 24: SAFETY ISSUES WITH RNAI CROP IMPROVEMENT
    • RNAi In Crops
      • TABLE 25: PLANT IMPROVEMENT AREAS THROUGH RNAI TECHNOLOGIES
      • TABLE 26: REGIONS, GENES AND APPLICATION OF RNAI-TARGETING ORGANISMS FOR IMPROVEMENT OF CROPS
    • RNAi In Aquaculture
    • Market Overview
  • MARKET BY REGION
    • MARKET OVERVIEW
    • MARKET REVENUE
      • RNAi Research Tools and Reagents
        • TABLE 27: GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS BY REGION, THROUGH 2020 ($ MILLIONS)
        • FIGURE 9: GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2013-2020 ($ MILLIONS)
      • Market Share
        • TABLE 28: GLOBAL MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2014 (%)
        • FIGURE 10: GLOBAL MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2014 (%)
      • RNAi Diagnostics
        • TABLE 29: GLOBAL REVENUE FOR RNAI DIAGNOSTICS BY REGION, THROUGH 2020 ($ MILLIONS)
        • FIGURE 11: GLOBAL REVENUE FOR RNAI DIAGNOSTICS BY REGION, 2013-2020 ($ MILLIONS)
      • Market Share
        • TABLE 30: GLOBAL MARKET SHARE OF RNAI DIAGNOSTICS BY REGION, 2014 (%)
        • FIGURE 12: GLOBAL MARKET SHARE OF RNAI DIAGNOSTICS BY REGION, 2014 (%)

CHAPTER 6 - INDUSTRY STRUCTURE

  • RNAI RESEARCH TOOLS AND REAGENTS
    • MARKET LEADERS
      • TABLE 31: LEADING MANUFACTURERS/SUPPLIERS OF RNAI RESEARCH TOOLS AND REAGENTS, 2014
    • MARKET SHARES
      • TABLE 32: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
      • FIGURE 13: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
  • RNAI DIAGNOSTICS
    • MARKET LEADERS
      • TABLE 33: LEADING MANUFACTURERS/SUPPLIERS OF RNAI DIAGNOSTICS, 2014
    • MARKET SHARES
      • TABLE 34: MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI DIAGNOSTICS, 2014 (%)
      • FIGURE 14: MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI DIAGNOSTICS, 2014 (%)

CHAPTER 7 - PATENT ANALYSIS

  • PATENTS BY YEAR
    • TABLE 35: TOTAL NUMBER OF PATENTS BY YEAR, 2013-AUGUST 2015
    • FIGURE 15: TOTAL NUMBER OF PATENTS BY YEAR, 2013-AUGUST 2015
  • PATENTS BY COUNTRY FOR RNA INTERFERENCE TECHNOLOGIES
    • TABLE 36: NUMBER OF U.S. PATENTS FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015
    • TABLE 37: PATENT SHARES FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015 (%)
    • FIGURE 16: PATENT SHARES FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015 (%)
  • PATENTS BY COMPANY FOR RNA INTERFERENCE TECHNOLOGIES
    • TABLE 38: NUMBER OF U.S. PATENTS FOR RNAI TECHNOLOGIES BY COMPANY, 2013-AUGUST 2015
  • PATENTS BY ASSIGNEE FOR RNA INTERFERENCE TECHNOLOGIES
    • TABLE 39: NUMBER OF PATENTS FOR RNAI TECHNOLOGIES BY TYPE OF ASSIGNEE, 2013-AUGUST 2015
    • FIGURE 17: NUMBER OF PATENTS FOR RNAI TECHNOLOGIES BY TYPE OF ASSIGNEE, 2013-AUGUST, 2015

CHAPTER 8 - CURRENT STATUS

  • INNOVATIVE TECHNOLOGIES AND PLATFORMS FOR RNA INTERFERENCE
  • DYNAMIC POLYCONJUGATE (DPC) PLATFORM-ARROWHEAD RESEARCH CORP.)
  • CONJUGATE DELIVERY PLATFORMS - ESC-GALNAC-CONJUGATE (ALNYLAM PHARMACEUTICALS INC.)
  • LIPID NANOPARTICLE (LNP) TECHNOLOGY (ARBUTUS BIOPHARMA CORP)
  • SIRNA TECHNOLOGY PLATFORM (QUARK PHARMACEUTICALS INC.)
  • MODIFIED MESSENGER RNA THERAPEUTICS PLATFORM (MODERNA THERAPEUTICS)
  • RNAI TECHNOLOGY PLATFORMS (GE DHARMACON)
    • On-TARGETplus siRNAs
    • Reverse Transfection Format (RTF) siRNA Libraries
    • Cherry-Pick RNAi Libraries
    • Human siRNA Libraries
    • Custom siRNA Synthesis
    • Accell siRNA
    • Mouse Accell siRNA Library - Protein Kinases
    • siGENOME siRNAs
    • Lincode siRNAs
    • Lincode siRNA Libraries
    • SMARTvector Lentiviral shRNA
    • SMARTvector Inducible Lentiviral shRNA
    • SMARTvector Lentiviral shRNA Pooled Libraries
    • GIPZ Lentiviral shRNA
    • TRIPZ Inducible Lentiviral shRNA
    • The RNAi Consortium (TRC) Lentiviral shRNA Library
    • Decode Pooled Lentiviral shRNA Screening Libraries and Reagents
    • Viral Packaging Kits
    • siRNA and microRNA Transfection Reagents
    • DharmaFECT Duo Transfection Reagent
  • RNAI TECHNOLOGIES (THERMO FISHER SCIENTIFIC)
    • Silencer Select siRNA
    • Silencer Select siRNA Libraries
    • Stealth RNAi siRNAs
    • BLOCK-iT siRNAs
    • Controls for RNAi Mechanism
  • RNAI TOOLS FROM SIGMA-ALDRICH
    • MISSION siRNA
    • Pre-arrayed siRNA Libraries
    • MISSION In Vivo Quality and iScale Oligos siRNA
    • N-TER Nanoparticle siRNA Transfection System
    • siRNA Controls (Positive and Negative)
    • MISSION shRNA Library
    • MISSION Lentiviral Controls
    • MISSION esiRNA
    • MISSION Human miRNA Mimics
  • LOCKED NUCLEIC ACID (LNA) PLATFORM (ROCHE [SANTARIS PHARMA])
  • TRIFECTA RNAI KIT (INTEGRATED DNA TECHNOLOGIES)
  • PSITEST SYSTEM (INVIVOGEN)
  • SELF-DELIVERABLE RNAI TECHNOLOGY (ADVIRNA)
  • RNAI TECHNOLOGIES (BIONEER CORP)
    • AccuTarget Libraries
    • AccuTarget Control siRNAs from Bioneer
    • AccuTarget Human miRNA Mimic and Inhibitor Library
    • Self-Assembled Micelle Inhibitory RNA (SAMiRNA)
  • POOLED LENTIVIRAL LIBRARIES (CELLECTA INC.)
  • NANOPARTICLE-DRUG CONJUGATES (NDCS) (CERULEAN PHARMA INC.)
  • ALLSTARS RNAI CONTROLS (QIAGEN N.V.)
  • RNAI TECHNOLOGIES (APPLIED BIOLOGICAL MATERIALS)
    • siRNA Adeno-Associated Virus (AAV)
    • iLenti RNAi Expression System
  • LIPID-ENABLED AND UNLOCKED NUCLEIC ACID MODIFIED RNA DELIVERY TECHNOLOGY (ARCTURUS THERAPEUTICS, INC.)
  • ELASTIN-LIKE POLYPEPTIDE (ELP) NANOPARTICLES (PEPTIMED INC.)
  • MICRORNA-BASED DIAGNOSTIC TESTS (ROSETTA GENOMICS)
    • The Rosetta Cancer Origin Test
    • The Rosetta Lung Cancer Test
    • The Rosetta Kidney Cancer Test
    • The Rosetta Mesothelioma Test
  • ATURNAI (SILENCE THERAPEUTICS)
  • DSIRNA-EX-CONJUGATES (DICERNA PHARMACEUTICALS INC.)
  • LODER (SILENSEED LTD.)
  • FACTORS AFFECTING THE RNA INTERFERENCE MARKET
  • CURRENT DRIVERS FOR THE RNA INTERFERENCE TECHNOLOGY MARKET
  • MERGER AND ACQUISITION ACTIVITIES
  • FUNDING FOR DEVELOPMENT OF RNA INTERFERENCE THERAPEUTICS AND TECHNOLOGIES
    • TABLE 40: FUNDING FOR DEVELOPMENT OF RNAI-BASED PRODUCTS AND PLATFORMS, 2013-SEPTEMBER 2015
    • TABLE 41: INVESTMENTS FOR DEVELOPMENT OF RNAI-BASED PRODUCTS AND PLATFORMS, 2013-SEPTEMBER 2015

CHAPTER 9 - COMPANY PROFILES

  • ADVIRNA
  • ALNYLAM PHARMACEUTICALS, INC.
  • APEIRON BIOLOGICS AG
  • APPLIED BIOLOGICAL MATERIALS, INC.
  • ARBUTUS BIOPHARMA CORP. (PREVIOUSLY TEKMIRA PHARMACEUTICALS CORP.)
  • ARCTURUS THERAPEUTICS, INC.
  • ARROWHEAD RESEARCH CORP.
  • ASCLETIS INC.
  • BENITEC BIOPHARMA LTD.
  • BIOGEN IDEC, INC.
  • BIOMICS BIOTECHNOLOGIES CO. LTD.
  • BIONEER CORP.
  • CELLECTA, INC.
  • CERULEAN PHARMA, INC.
  • DICERNA PHARMACEUTICALS, INC.
  • EXIQON A/S
  • F. HOFFMANN-LA ROCHE AG (ROCHE)
  • GENERAL ELECTRIC CO.
  • INTEGRATED DNA TECHNOLOGIES, INC.
  • INVIVOGEN
  • ISIS PHARMACEUTICALS, INC.
  • MARINA BIOTECH, INC.
  • MODERNA THERAPEUTICS
  • MONSANTO CO.
  • NITTO DENKO CORP.
  • PEPTIMED INC.
  • QIAGEN N.V.
  • QUARK PHARMACEUTICALS, INC.
  • REGULUS THERAPEUTICS
  • ROSETTA GENOMICS LTD.
  • RXI PHARMACEUTICALS CORP.
  • SANOFI
  • SIGMA-ALDRICH
  • SILENCE THERAPEUTICS PLC.
  • SILENSEED LTD.
  • SOLSTICE BIOLOGICS
  • SOMAGENICS, INC.
  • SUMITOMO DAINIPPON PHARMA CO. LTD.
  • SYNGENTA INTERNATIONAL AG
  • THE NATIONAL INSTITUTES OF HEALTH (NIH)
  • THE RNAI CONSORTIUM AT BROAD INSTITUTE OF MIT AND HARVARD
  • THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
  • THERMO FISHER SCIENTIFIC, INC.
  • ZELTIA GROUP

CHAPTER 10 - APPENDIX

  • GLOSSARY AND ABBREVIATIONS

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 1: EVOLUTION OF RNA
    • TABLE 2: MICRORNA (MIRNA) DATABASES
    • TABLE 3: SHORT/SMALL INTERFERING RNA (SIRNA) DATABASES
    • TABLE 4: PIWI-INTERACTING RNA (PIRNA) DATABASES
    • TABLE 5: STABILIZATION METHODS FOR LIPID BASED SIRNA DELIVERY SYSTEM
    • TABLE 6: NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF RNAI THERAPEUTICS AND TECHNOLOGIES AS OF SEPTEMBER 2015
    • TABLE 7: GLOBAL REVENUE FOR RNAI TECHNOLOGIES BY TYPE, THROUGH 2020 ($ MILLIONS)
    • TABLE 8: MARKET SHARE OF RNAI TECHNOLOGIES BY TYPE, 2014 (%)
    • TABLE 9: MODIFICATIONS OF SIRNA
    • TABLE 10: RNAI VECTORS
    • TABLE 11: GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS, THROUGH 2020 ($ MILLIONS)
    • TABLE 12: MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
    • TABLE 13: DISEASE-SPECIFIC TARGET GENES/PROTEINS FOR RNAI THERAPEUTICS
    • TABLE 14: GLOBAL PHARMACEUTICAL MARKET, THROUGH 2020 ($ BILLIONS)
    • TABLE 15: GLOBAL PHARMACEUTICAL MARKET SHARES BY REGION, 2014 (%)
    • TABLE 16: TOP GLOBAL PHARMACEUTICAL COMPANIES BY SALES, 2014 ($ MILLIONS)
    • TABLE 17: GLOBAL OUTLOOK OF THERAPEUTIC SPENDING BY DISEASE, THROUGH 2018 ($ BILLION/%)
    • TABLE 18: NUMBER OF PUBLICATIONS ASSOCIATED WITH MIRNA AND DISEASES, OCTOBER 2015
    • TABLE 19: MIRNA IN VARIOUS CANCER TYPES
    • TABLE 20: MIRNA AND TARGET GENE PAIRS IN VARIOUS CANCER TYPES
    • TABLE 21: BIOMARKERS IN VARIOUS CANCER TYPES
    • TABLE 22: GLOBAL REVENUE MARKET FOR RNAI DIAGNOSTICS, THROUGH 2020 ($ MILLIONS)
    • TABLE 23: GLOBAL REVENUE FOR MIRNA RESEARCH TOOLS, THROUGH 2020 ($ MILLIONS)
    • TABLE 24: SAFETY ISSUES WITH RNAI CROP IMPROVEMENT
    • TABLE 25: PLANT IMPROVEMENT AREAS THROUGH RNAI TECHNOLOGIES
    • TABLE 26: REGIONS, GENES AND APPLICATION OF RNAI-TARGETING ORGANISMS FOR IMPROVEMENT OF CROPS
    • TABLE 27: GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 28: GLOBAL MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2014 (%)
    • TABLE 29: GLOBAL REVENUE FOR RNAI DIAGNOSTICS BY REGION, THROUGH 2020 ($ MILLIONS)
    • TABLE 30: GLOBAL MARKET SHARE OF RNAI DIAGNOSTICS BY REGION, 2014 (%)
    • TABLE 31: LEADING MANUFACTURERS/SUPPLIERS OF RNAI RESEARCH TOOLS AND REAGENTS, 2014
    • TABLE 32: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
    • TABLE 33: LEADING MANUFACTURERS/SUPPLIERS OF RNAI DIAGNOSTICS, 2014
    • TABLE 34: MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI DIAGNOSTICS, 2014 (%)
    • TABLE 35: TOTAL NUMBER OF PATENTS BY YEAR, 2013-AUGUST 2015
    • TABLE 36: NUMBER OF U.S. PATENTS FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015
    • TABLE 37: PATENT SHARES FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015 (%)
    • TABLE 38: NUMBER OF U.S. PATENTS FOR RNAI TECHNOLOGIES BY COMPANY, 2013-AUGUST 2015
    • TABLE 39: NUMBER OF PATENTS FOR RNAI TECHNOLOGIES BY TYPE OF ASSIGNEE, 2013-AUGUST 2015
    • TABLE 40: FUNDING FOR DEVELOPMENT OF RNAI-BASED PRODUCTS AND PLATFORMS, 2013-SEPTEMBER 2015
    • TABLE 41: INVESTMENTS FOR DEVELOPMENT OF RNAI-BASED PRODUCTS AND PLATFORMS, 2013-SEPTEMBER 2015

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL REVENUE FOR RNA INTERFERENCE TECHNOLOGIES BY TYPE, 2013-2020 ($ MILLIONS)
    • FIGURE 1: GLOBAL REVENUE FOR RNAI TECHNOLOGIES BY TYPE, 2013-2020 ($ MILLIONS)
    • FIGURE 2: MARKET SHARE OF RNAI TECHNOLOGIES BY TYPE, 2014 (%)
    • FIGURE 3: GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS, 2013-2020 ($ MILLIONS)
    • FIGURE 4: MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
    • FIGURE 5: GLOBAL PHARMACEUTICAL SALES MARKET,2013-2020 ($ BILLIONS)
    • FIGURE 6: GLOBAL PHARMACEUTICAL MARKET SHARES BY REGION, 2014 (%)
    • FIGURE 7: GLOBAL REVENUE MARKET FOR RNAI DIAGNOSTICS, 2013-2020 ($ MILLIONS)
    • FIGURE 8: GLOBAL REVENUE FOR MIRNA RESEARCH TOOLS,2013-2020 ($ MILLIONS)
    • FIGURE 9: GLOBAL REVENUE FOR RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 10: GLOBAL MARKET SHARE OF RNAI RESEARCH TOOLS AND REAGENTS BY REGION, 2014 (%)
    • FIGURE 11: GLOBAL REVENUE FOR RNAI DIAGNOSTICS BY REGION, 2013-2020 ($ MILLIONS)
    • FIGURE 12: GLOBAL MARKET SHARE OF RNAI DIAGNOSTICS BY REGION, 2014 (%)
    • FIGURE 13: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI RESEARCH TOOLS AND REAGENTS, 2014 (%)
    • FIGURE 14: MARKET SHARES OF MANUFACTURERS/SUPPLIERS FOR RNAI DIAGNOSTICS, 2014 (%)
    • FIGURE 15: TOTAL NUMBER OF PATENTS BY YEAR, 2013-AUGUST 2015
    • FIGURE 16: PATENT SHARES FOR RNAI TECHNOLOGIES BY COUNTRY, 2013-AUGUST 2015 (%)
    • FIGURE 17: NUMBER OF PATENTS FOR RNAI TECHNOLOGIES BY TYPE OF ASSIGNEE, 2013-AUGUST, 2015
Back to Top